KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Non-Current Debt: 2019-2024

Historic Non-Current Debt for Rigel Pharmaceuticals (RIGL) over the last 6 years, with Dec 2024 value amounting to $52.4 million.

  • Rigel Pharmaceuticals' Non-Current Debt fell 49.85% to $30.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30.0 million, marking a year-over-year decrease of 49.85%. This contributed to the annual value of $52.4 million for FY2024, which is 0.07% up from last year.
  • According to the latest figures from FY2024, Rigel Pharmaceuticals' Non-Current Debt is $52.4 million, which was up 0.07% from $52.4 million recorded in FY2023.
  • In the past 5 years, Rigel Pharmaceuticals' Non-Current Debt registered a high of $52.4 million during FY2024, and its lowest value of $19.8 million during FY2020.
  • Over the past 3 years, Rigel Pharmaceuticals' median Non-Current Debt value was $52.4 million (recorded in 2023), while the average stood at $48.1 million.
  • Data for Rigel Pharmaceuticals' Non-Current Debt shows a peak YoY surged of 101.99% (in 2020) over the last 5 years.
  • Yearly analysis of 5 years shows Rigel Pharmaceuticals' Non-Current Debt stood at $19.8 million in 2020, then rose by 0.50% to $19.9 million in 2021, then surged by 98.09% to $39.4 million in 2022, then surged by 32.76% to $52.4 million in 2023, then grew by 0.07% to $52.4 million in 2024.